Sodium-glucose co-transporter 2 (SGLT2) inhibitors

PheWeb

SGLT2INH

No definition available.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Medicine purchases: ATC A10BJ

3436

Check pre-conditions, main-only, mode, ICD version None

3084

Check minimum number of events

Min. number of events 3

3084

Include endpoints None

3084

SGLT2INH

Extra metadata

First used in FinnGen datafreeze DF2

Similar endpoints

↥

List of similar endpoints to Sodium-glucose co-transporter 2 (SGLT2) inhibitors based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

All

Female

Male

Number of individuals

2997

1510

1487

Unadjusted prevalence (%)

0.97

0.87

1.10

Mean age at first event (years)

61.34

60.29

62.40

?

Follow-up

Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.

Absolute risk

Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).

Number of individuals (N)

Number of individuals having the current endpoint and died during the follow-up time.
Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.04	2.88 [1.80, 4.60]	1.0e-5	39
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: SGLT2INH – Sodium-glucose co-transporter 2 (SGLT2) inhibitors
GWS hits:

Survival analyses between endpoints

↥

Plot

before Sodium-glucose co-transporter 2 (SGLT2) inhibitors
after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Sodium-glucose co-transporter 2 (SGLT2) inhibitors

↥